First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288

1 Like

It’s hard for me to follow the article but I’m guessing it’s good news?

So if it makes it this med should take another ten years. It’s only in phase 1. We’ve got a ways to go